Order Article Reprints

Gentile I, Scotto R, Schiano Moriello N, Pinchera B, Villari R, Trucillo E, Ametrano L, Fusco L, Castaldo G, Buonomo AR, et al. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Vaccines. 2022; 10(10):1731. https://doi.org/10.3390/vaccines10101731

Gentile, Ivan, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, and et al. 2022. "Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study" Vaccines 10, no. 10: 1731. https://doi.org/10.3390/vaccines10101731

Gentile, I., Scotto, R., Schiano Moriello, N., Pinchera, B., Villari, R., Trucillo, E., Ametrano, L., Fusco, L., Castaldo, G., Buonomo, A. R., & Federico II COVID Team. (2022). Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Vaccines, 10(10), 1731. https://doi.org/10.3390/vaccines10101731